George D. Yancopoulos net worth and biography

George Yancopoulos Biography and Net Worth

George D. Yancopoulos, MD, PhD, has built and managed Regeneron alongside Dr. Schleifer since 1989. Dr. Yancopoulos is currently President and Chief Scientific Officer and has served on the board since 2001. Dr. Yancopoulos, along with key members of his team, is the principal inventor of Regeneron’s eight FDA-approved drugs and foundational technologies, including the TRAP technology, VelociGene® and VelocImmune®. He has been named an Ernst & Young Entrepreneur of the Year and has been pivotal in creating the science-driven, collaborative and highly-productive R&D culture at Regeneron. This unique environment has earned the company widespread recognition, including repeatedly being named one of the “most innovative companies in the world” by Forbes magazine. Dr. Yancopoulos was the 11th most highly cited scientist in the world in the 1990s, and in 2004 he was elected to be a member of the National Academy of Sciences. Dr. Yancopoulos attended the Bronx High School of Science and received his MD and PhD from Columbia University.

What is George D. Yancopoulos' net worth?: The estimated net worth of George D. Yancopoulos is at least $126.33 million as of January 2nd, 2024. Dr. Yancopoulos owns 180,000 shares of Regeneron Pharmaceuticals stock worth more than $126,333,000 as of December 21st. This net worth estimate does not reflect any other assets that Dr. Yancopoulos may own. Additionally, Dr. Yancopoulos receives a salary of $7,760,000.00 as Insider at Regeneron Pharmaceuticals. Learn More about George D. Yancopoulos' net worth.
How old is George D. Yancopoulos?: Dr. Yancopoulos is currently 64 years old. There are 5 older executives and no younger executives at Regeneron Pharmaceuticals. The oldest executive at Regeneron Pharmaceuticals is Dr. Leonard S. Schleifer M.D., Ph.D., Co-Founder, President, CEO & Co-Chairman, who is 71 years old. Learn More on George D. Yancopoulos' age.
What is George D. Yancopoulos' salary?: As the Insider of Regeneron Pharmaceuticals, Inc., Dr. Yancopoulos earns $7,760,000.00 per year. The highest earning executive at Regeneron Pharmaceuticals is Dr. Leonard S. Schleifer M.D., Ph.D., Co-Founder, President, CEO & Co-Chairman, who commands a salary of $8,180,000.00 per year. Learn More on George D. Yancopoulos' salary.
How do I contact George D. Yancopoulos?: The corporate mailing address for Dr. Yancopoulos and other Regeneron Pharmaceuticals executives is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. Regeneron Pharmaceuticals can also be reached via phone at (914) 847-7000 and via email at [email protected]. Learn More on George D. Yancopoulos' contact information.
Has George D. Yancopoulos been buying or selling shares of Regeneron Pharmaceuticals?: George D. Yancopoulos has not been actively trading shares of Regeneron Pharmaceuticals during the last ninety days. Most recently, George Yancopoulos sold 16,848 shares of the business's stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $900.00, for a transaction totalling $15,163,200.00. Following the completion of the sale, the insider now directly owns 180,000 shares of the company's stock, valued at $162,000,000. Learn More on George D. Yancopoulos' trading history.
Who are Regeneron Pharmaceuticals' active insiders?: Regeneron Pharmaceuticals' insider roster includes Bonnie Bassler (Director), Michael Brown (Director), N. Coles (Director), Christopher Fenimore (VP), Joseph Goldstein (Director), Robert Landry (CFO), Joseph Larosa (EVP), Marion Mccourt (EVP), Andrew Murphy (EVP), Christine Poon (Director), Arthur Ryan (Director), Leonard Schleifer (CEO), George Sing (Director), Neil Stahl (EVP), Marc Tessier-Lavigne (Director), P. Vagelos (Director), Daniel Van Plew (EVP), George Yancopoulos (Insider), and Huda Zoghbi (Director). Learn More on Regeneron Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Regeneron Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 27 times. They sold a total of 107,995 shares worth more than $105,556,492.64. The most recent insider tranaction occured on August, 28th when CFO Christopher R Fenimore sold 5,680 shares worth more than $6,846,274.40. Insiders at Regeneron Pharmaceuticals own 7.5% of the company. Learn More about insider trades at Regeneron Pharmaceuticals.
Information on this page was last updated on 8/28/2024.

George D. Yancopoulos Insider Trading History at Regeneron Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/2/2024	Sell	16,848	$900.00	$15,163,200.00	180,000
3/23/2023	Sell	3,656	$804.26	$2,940,374.56	196,848
2/6/2023	Sell	13,189	$800.08	$10,552,255.12	200,504
8/5/2021	Sell	50,000	$600.06	$30,003,000.00	937,483
6/21/2021	Sell	80,000	$538.90	$43,112,000.00	987,483
12/2/2015	Sell	43,348	$549.03	$23,799,352.44	500,000
11/2/2015	Sell	43,348	$571.61	$24,778,150.28	543,348
2/12/2014	Sell	88,987	$320.33	$28,505,205.71	1,068,343

George D. Yancopoulos Buying and Selling Activity at Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Company Overview

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Today's Range

Now: $701.85

$700.83

$717.61

50 Day Range

MA: $821.00

$701.85

$1,016.53

2 Week Range

Now: $701.85

$693.00

$1,211.20

Volume

1,889,979 shs

Average Volume

568,354 shs

Market Capitalization

$77.13 billion

P/E Ratio

17.37

Dividend Yield

N/A

Beta

0.08

Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong

From Brownstone Research | Ad

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.

George Yancopoulos Biography and Net Worth

What is George D. Yancopoulos' net worth?

How old is George D. Yancopoulos?

What is George D. Yancopoulos' salary?

How do I contact George D. Yancopoulos?

Has George D. Yancopoulos been buying or selling shares of Regeneron Pharmaceuticals?

Who are Regeneron Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Regeneron Pharmaceuticals?